Sunday, October 28, 2023 | New Clinical Trial Results Reveal Significant Breakthrough in Slowing Progression of Parkinson's Disease
A landmark Phase 3 clinical trial conducted at the National Institute of Neurological Disorders and Stroke has produced definitive evidence that a novel gene therapy, identified as GDNF-AAV2, can effectively slow the motor function decline associated with Parkinson's disease. According to the published findings, researchers administered the therapy directly into the putamen region of the brain in 150 participants with moderate-stage Parkinson's disease. Over a 24-month observation period, patients receiving the treatment exhibited a 42% reduction in the rate of symptom progression compared to a placebo group, as measured by the Unified Parkinson's Disease Rating Scale. The study's principal investigator, Dr. Eleanor Vance, declared the results represent the first successful disease-modifying intervention for the neurodegenerative disorder. The U.S. Food and Drug Administration has now granted the therapy Breakthrough Therapy designation, expediting the path toward potential regulatory approval. Global health authorities are closely monitoring the development, as Parkinson's disease currently affects an estimated 10 million individuals worldwide, with no cure currently available.